Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lixisenatide as a Growth Hormone Stimulation Test
NCT05804513Phase 4Unknown
- Sponsor
- University of Tartu
- Start
- Apr 2023
- Primary completion
- Oct 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 4 trial of lixisenatide in growth hormone deficiency (GHD), sponsored by University of Tartu. Status: unknown.
02
Drugs
lixisenatide
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT05804513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05804513.